ClinicalTrials.gg
RecruitingNCT07198594OCDTMS-IFCUpdated Sep 30, 2025

Accelerated rTMS Therapeutic Approach for Refractory Obsessive-Compulsive Disorder

An interventional study of rTMS in Obsessive Compulsive Disorder (OCD) and Obsessive - Compulsive Disorder, sponsored by Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-09-30.

Sponsored by Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Obsessive-Compulsive Disorder with a site in China — 25 open to participants now, 26 under way, none of them phase 3. Obsessive-Compulsive Disorder · China.

Planned enrollment
41st of 49
20 · median 60
Started
2025
with 4 others
No phase
40 of 52
23 open now
Primary completion
2026-12
later than 10 of 25 live
Registered
45th of 52
by date

Among the 52 studies in Obsessive-Compulsive Disorder with a site in China, this one is the 41st largest by planned enrollment of the 49 interventional ones that give a count, is one of 5 that started in 2025, is one of 40 with no phase, reaches primary completion later than 10 of the 25 other live ones, and was the 45th registered.

Obsessive-Compulsive Disorder

637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.

Browse Obsessive-Compulsive Disorder studies →

Open to participants now

25 of the 52 studies in Obsessive-Compulsive Disorder with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Obsessive-Compulsive Disorder with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if individualized accelerated repetitive transcranial magnetic stimulation (rTMS) targeting the inferior frontal cortex combined with symptom provocation works to treat obsessive-compulsive disorders (OCD) in adults. It will also learn about the safety of rTMS over right IFC. The main questions it aims to answer are:

  • Does rTMS using a new individualized IFC target relieve participants' OCD symptoms?
  • What medical problems do participants have when taking rTMS?

Participants will:

  • Take rTMS six times per day for 5 consecutive days
  • Visit the clinic once at baseline, the day and four weeks after treatment for checkups and tests
03

Conditions studied

  • Obsessive Compulsive Disorder (OCD)
  • Obsessive - Compulsive Disorder
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Volunteer subjects with Obsessive Compulsive Disorders (OCD) according to the (DSM V) criteria
  • without associated tics ("Gilles de la Tourette" Syndrome)
  • Age 18-60 years, right-handed
  • Disease severity: Yale-Brown Obsessive Compulsive Scale score ≥16 for OCD patients
  • Medication stable for at least 4 weeks
  • Resistant patients to standard treatments: partial but insufficient response (reduction of Y-BOCS score \< 35%) or lack of response to previous well conducted treatment including: optimal tolerated dose and adequate duration (> 12 weeks) of at least 2 Serotonin Reuptake Inhibitors (selective serotonin reuptake inhibitors, clomipramine), or 1 Serotonin Reuptake Inhibitors + 1 augmentation strategy (adjunction of an antipsychotic - such as risperidone or olanzapine or aripiprazole - or lithium or buspirone)
  • No systematic rTMS therapy in the past six months;
  • Signature of form;
  • Normal vision or corrected vision;
  • Capacity to complete protocol-specified tests.

Exclusion criteria

Exclusion Criteria:

  • Abnormal cognitive status (assessed using with score \<24);
  • Other primary diagnosis than OCD (comorbid mild depression is tolerated)
  • Comorbid diagnosis of schizophrenia/ psychotic disorder, bipolar disorder, substance abuse or dependance3)
  • Significant self-harm intent or severe suicidal tendencies within the past year;
  • Irreversible visual or auditory impairment preventing completion of scales or related assessments;
  • Presence of metallic implants, such as pacemakers or stents;
  • Any current or potential medical, psychological, social, or geographical factors compromising patient safety or study participation;
  • Poor compliance;
  • Claustrophobia;
  • History of epilepsy or familial epilepsy
  • Pregnant or lactating women (women of must obtain a negative pregnancy test result prior to study commencement and employ medically approved measures);
  • Deterioration or failure of vital organ function (cardiac, pulmonary, hepatic, renal, etc.); or unstable vital signs;
  • Conditions unsuitable for this stimulation site, such as increased intracranial pressure, elevated intraocular pressure, or glaucoma
  • History of or concomitant neurological disorders: cerebrovascular disease, central nervous system infections, Creutzfeldt-Jakob disease, Huntington's disease and Parkinson's disease, Lewy body dementia, traumatic brain injury dementia, other physical/chemical factors (drugs, alcohol, CO, etc.), significant somatic diseases (hepatic encephalopathy, pulmonary encephalopathy, etc.), intracranial space-occupying lesions (subdural haematoma, brain tumours), endocrine system disorders (thyroid disease, parathyroid disease), and dementia caused by vitamin deficiency or any other cause
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    rTMS

    individualized rTMS targeting IFC, with symptom provocation

    Other: rTMS

Interventions

  • OtherrTMS

    individualized rTMS target the IFC with symptom provocation

06

What researchers measure

Primary outcomes

  1. OCD Symptom Severity Assessed by Y-BOCS

    Change from Baseline to 4 weeks after treatment in OCD Symptom Severity

    Time frame: From Baseline to 6 months after treatment

Secondary outcomes

  1. Safety for rTMS targeting IFC

    Number of Participants with Treatment-Related Adverse Events

    Time frame: Adverse Events after treatment

  2. Depression Severity Assessed by HAMD

    Time frame: From baseline to 4 weeks after treatment

  3. Anxitey Severity Assessed by HAMA

    Time frame: From Baseline to 4 weeks after treatment

  4. Clinical Efficacy Assessed by CGI

    Time frame: From Baseline to 4 weeks after treatment

  5. Uncertainty Assessed by IUI and IUS-12

    Time frame: From Baseline to 4 weeks after treatment

  6. Self-rated Beck Depression Inventory (BDI)

    Time frame: From Baseline to 4 weeks after treatment

  7. Self-rated State-Trait Anxiety Inventory (STAI)

    Time frame: From Baseline to 4 weeks after treatment

  8. Self-rated Short UPPS-P Impulsive Behaviour Scale

    Time frame: From baseline to 4 weeks after treatment

  9. Neuroimaging by Magnetic resonance imaging

    Time frame: From baseline to 4 weeks after treatment

  10. Cognitive Function Assessent by tasks

    Including Cantab and coded tasks in Matlab

    Time frame: From baseline to 4 weeks after treatment

07

Study locations

1 of 1 sites recruiting
  • Shanghai Pudong New Area Mental Health Centre
    Shanghai, Shanghai Municipality 200124, China
    Recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 235 non-industry interventional studies with no phase under Obsessive-Compulsive Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 63. This study's planned 17 months is below that.

Counting every sponsor, half of 238 studies reached it within 43 months; a quarter within 22 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2025
First posted
Sep 30, 2025
StartActual
Jul 3, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Sep 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07198594
Lead sponsor
Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University
Responsible party
zhaoyijie (Associate Professor, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University) — Principal investigator
First posted
Sep 30, 2025
Start date
Jul 3, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 30, 2025

Study contacts

Yijie Zhao
Contact
yj_zhao@tongji.edu.cn
+86 13585960699

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion